Xilio Therapeutics, Inc. (XLO): Free Cash Flow
-$5.51M
Year ended 2025-12-31
-$61.27M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$5.51M | n/m | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | -$18.41M | n/m | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | -$69.11M | n/m | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | -$77.59M | n/m | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | -$81.85M | n/m | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | -$38.28M | n/a | 2022-03-01, From 2020-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | -$5.51M | n/m |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $4.83M | n/m |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | -$52.99M | n/m |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | -$188.21M | n/m |
| Biofrontera Inc. (BFRI) | 2025-12-31 | -$13.36M | n/m |
| Septerna, Inc. (SEPN) | 2025-12-31 | $109.67M | n/m |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $56.08M | -69.3% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$171.34M | n/m |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | -$67.85M | n/m |
Compare XLO, CPIX, AQST, WVE side by side · Screen every company in Pharmaceutical Preparations ↗